<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(3)</volume><submitter>Munoz-Gomez E</submitter><pubmed_abstract>Background: Migraine is a common neurological disorder, and it is the second leading cause of disability worldwide. Manual techniques based on physical therapy have been proposed to improve migraine aspects; however, further research is needed on their effectiveness. The aim of this study was to evaluate the effectiveness of a craniosacral therapy protocol on different features in migraine patients. Methods: Fifty individuals with migraine were randomly divided into two groups (n = 25 per group): (i) craniosacral therapy group (CTG), following a craniosacral therapy protocol, and (ii) sham control group (SCG), with a sham treatment. The analyzed variables were pain, migraine severity and frequency of episodes, functional, emotional, and overall disability, medication intake, and self-reported perceived changes, at baseline, after a 4 week intervention, and at 8 week follow-up. Results: After the intervention, the CTG significantly reduced pain (p = 0.01), frequency of episodes (p = 0.001), functional (p = 0.001) and overall disability (p = 0.02), and medication intake (p = 0.01), as well as led to a significantly higher self-reported perception of change (p = 0.01), when compared to SCG. In addition, the results were maintained at follow-up evaluation in all variables. Conclusions: A protocol based on craniosacral therapy is effective in improving pain, frequency of episodes, functional and overall disability, and medication intake in migraineurs. This protocol may be considered as a therapeutic approach in migraine patients.</pubmed_abstract><journal>Journal of clinical medicine</journal><pagination>759</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8836770</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Effect of a Craniosacral Therapy Protocol in People with Migraine: A Randomized Controlled Trial.</pubmed_title><pmcid>PMC8836770</pmcid><pubmed_authors>Aguilar-Rodriguez M</pubmed_authors><pubmed_authors>Ingles M</pubmed_authors><pubmed_authors>Espi-Lopez GV</pubmed_authors><pubmed_authors>Molla-Casanova S</pubmed_authors><pubmed_authors>Serra-Ano P</pubmed_authors><pubmed_authors>Munoz-Gomez E</pubmed_authors><pubmed_authors>Sempere-Rubio N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effect of a Craniosacral Therapy Protocol in People with Migraine: A Randomized Controlled Trial.</name><description>Background: Migraine is a common neurological disorder, and it is the second leading cause of disability worldwide. Manual techniques based on physical therapy have been proposed to improve migraine aspects; however, further research is needed on their effectiveness. The aim of this study was to evaluate the effectiveness of a craniosacral therapy protocol on different features in migraine patients. Methods: Fifty individuals with migraine were randomly divided into two groups (n = 25 per group): (i) craniosacral therapy group (CTG), following a craniosacral therapy protocol, and (ii) sham control group (SCG), with a sham treatment. The analyzed variables were pain, migraine severity and frequency of episodes, functional, emotional, and overall disability, medication intake, and self-reported perceived changes, at baseline, after a 4 week intervention, and at 8 week follow-up. Results: After the intervention, the CTG significantly reduced pain (p = 0.01), frequency of episodes (p = 0.001), functional (p = 0.001) and overall disability (p = 0.02), and medication intake (p = 0.01), as well as led to a significantly higher self-reported perception of change (p = 0.01), when compared to SCG. In addition, the results were maintained at follow-up evaluation in all variables. Conclusions: A protocol based on craniosacral therapy is effective in improving pain, frequency of episodes, functional and overall disability, and medication intake in migraineurs. This protocol may be considered as a therapeutic approach in migraine patients.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2025-04-04T07:50:52.17Z</modification><creation>2025-04-04T07:50:52.17Z</creation></dates><accession>S-EPMC8836770</accession><cross_references><pubmed>35160211</pubmed><doi>10.3390/jcm11030759</doi></cross_references></HashMap>